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Abstract. death receptor-3 (dr3) and death decoy 
receptor-3 (dcr3) are both members of the tumour necrosis 
factor receptor (tnFr) superfamily. the tnFr superfamily 
contains eight death domain-containing receptors, including 
tnFr1 (also called dr1), Fas (also called dr2), dr3, 
dr4, dr5, dr6, nGFr and Edar. upon the binding of 
these receptors with their corresponding ligands, the death 
domain recruits various proteins that mediate both the death 
and proliferation of cells. receptor function is negatively 
regulated by decoy receptors (dcr1, dcr2, dcr3 and 
OpG). dr3/dcr3 are a pair of positive and negative players 
with which vascular endothelial growth inhibitor (VEGi) 
interacts. VEGi has been suggested to be a potential tumour 
suppressor. the inhibitory effects of VEGi on cancer are 
manifested in three main areas: a direct effect on cancer 
cells, an anti-angiogenic effect on endothelial cells, and 
the stimulation of dendritic cell maturation. a recent study 
indicated that dr3 may be a new receptor for E-selectin, 
which has been reported to be associated with cancer 
metastasis. dcr3 is a soluble receptor, highly expressed in 
various tumours, which lacks an apparent transmembrane 
segment, prevents cytokine response through ligand binding 
and neutralization, and is an inhibitor of apoptosis. dcr3 
serves as a decoy receptor for Fasl, liGht and VEGi. the 
cytokine liGht activates various anti-tumour functions and 
is expected to be a promising candidate for cancer therapy. 
certain tumours may escape Fasl-dependent immune-
cytotoxic attack by expressing dcr3, which blocks Fasl 
function. dr3/dcr3 play profound roles in regulating cell 
death and proliferation in cancer. The present review briefly 
discusses dr3/dcr3 and attempts to elucidate the role of 
these negative and positive players in cancer.
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1. Introduction
Death receptor-3 (DR3) was first identified in 1996 (1-3) and 
was named apo-3; it is also termed as lard, tramp, WS-1, 
tr3 and tnFrSF25. dr3 was found to be a transmembrane 
protein of approximately 47 kda sharing similar extra-
cellular cysteine-rich domains with other members of the 
tumour necrosis factor receptor (tnFr) family. in addition, 
DR3 resembles TNFR1 and CD95, in that it contains a cyto-
plasmic death domain. dr3 was thought to be the receptor for 
tWEaK in an early experiment (4), but later studies disproved 
this hypothesis (5,6). 
currently, dr3 is known as the functional receptor of 
vascular endothelial growth inhibitor (VEGi) (7,8). recent 
studies have revealed a profound implication of VEGi in 
clinical cancer. the expression and effects of VEGi have 
been investigated in a wide variety of human cancer cell lines, 
including breast, prostate, bladder, colorectal and liver cancer 
cells (9). However, the mechanism of action of VEGI in cancer 
remains unclear. activated dr3 has been shown to induce 
rapid apoptosis by activating the caspase cascade through inter-
action with tradd and Fadd (1-3,10,11). like other tnFr 
family members, dr3 is also able to induce nuclear factor κB 
(nF-κB) and to promote cell survival signals via tradd and 
traF2 (2,8,11,12). however, a recent study showed that dr3 
may be a new receptor for E-selectin, which has been linked 
with cancer metastasis. The findings of this study indicate that 
the activation of dr3 in response to E-selectin triggers the 
transendothelial migration of cancer cells and protects them 
against apoptosis, suggesting that dr3 has evolved to provide 
metastatic advantages to colon cancer cells (13). 
Death decoy receptor-3 (DcR3) was first detected in 1998 
in human lung and colon tumours as a decoy receptor that 
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binds to Fasl and inhibits Fasl-induced apoptosis. it is also 
known as tr6 or m68 (14). currently, dcr3 is known to be 
a soluble receptor and a secreted protein belonging to the 
tnFr superfamily, and is a decoy receptor for VEGi, Fasl 
and liGht (8,14-16). dcr3 lacks transmembrane and cyto-
plasmic domains in its sequence. Wu et al found that serum 
DcR3 was negative in 97.9% (47/48) of healthy individuals and 
patients with acute infection and positive in 56% of tumour 
patients, while >70% of patients with gastric, liver and gall-
bladder carcinomas had elevated serum dcr3 levels (>20 pg/
ml) (17). tumour cells engineered to release high amounts of 
dcr3 are protected from apoptosis and chemotaxis, which 
in turn results in a decreased immune response to the th2 
phenotype (18-21). this suggests that dcr3 is involved in the 
progression and immune evasion of malignant tumours. 
2. Structure of DR3 and DcR3
dr3 is a transmembrane protein of which at least 11 distinct 
isoforms, generated by alternative splicing, exist. the major 
isoform has a molecular weight of 47 kda (22). the dr3 
gene has been mapped to human chromosome 1p36.3 (2,3). 
dr3 protein has a signal sequence (amino acids 1-24), 
followed by an extracellular region (amino acids 25-198), 
a transmembrane domain (amino acids 199-224) and an 
intracellular region (amino acids 225-417). the extracellular 
domain (Ecd) contains four cysteine-rich pseudorepeats 
which resemble the corresponding regions of human tnFr1 
(four repeats) and CD95 (three repeats). The intracellular 
domain (icd) contains a sequence which resembles the death 
domains found in the ICDs of TNFR1 and CD95 and in other 
death signaling proteins, such as human Fadd/mOrt1, 
tradd, rip and drosophila reaper. notably, four out of the 
six amino-acid residues in the death domain of tnFr1 that 
are essential for signaling [F345, r347, l351 and W378 (23)] 
are identical in dr3 (F350, r352, l356 and W382), whereas 
the remaining two TNFR1 residues [E369 and 1408 (23)] 
are semi-conserved in DR3 (D371 and L409). The sequence 
homology between DR3 and TNFR1 is particularly high: 40% 
in the death domain and 22% in the extracellular cysteine-rich 
domain (22). 
In 1998, Pitti et al isolated a previously unknown full-
length complementary dna from human fetal lung (14), and 
named the protein encoded by this cdna dcr3. the dcr3 
gene was mapped to human chromosome 20q13. the cdna 
encodes a 300-amino-acid polypeptide which belongs to the 
tnFr family (14). the amino terminus contains a leader 
sequence, which is followed by four tandem cysteine-rich 
domains (crds). this is similar to another tnFr homo-
logue, osteoprotegerin (OpG) (24). dcr3 is a protein with a 
relative molecular mass of 35 kda and lacks an apparent trans-
membrane sequence. all of the cysteines in the four crds of 
dcr3 and OpG are conserved; however, the carboxy-terminal 
portion of dcr3 is 101 residues shorter. 
3. Ligands of DR3 and DcR3 
VEGI is a recently identified anti-angiogenic cytokine that 
was first detected in 1999 in human umbilical vein endothe-
lial cells, and  belongs to the tnF superfamily. VEGi is also 
known as tumour necrosis factor superfamily member 15 
(tnFSF15) and tnF ligand-related molecule 1 (tl1) (7,25). 
VEGi binds to dr3 and subsequently triggers intracellular 
events, which can be blocked by dcr3. VEGi has been 
extensively studied in immune disorders. recent investiga-
tions have highlighted a potential cancer inhibitory role for 
this cytokine. the inhibitory effects of VEGi on cancer are 
manifested in three main areas: direct inhibition of cancer 
cell proliferation, anti-angiogenic effects on endothelial cells 
and the stimulation of dendritic cell maturation. VEGi is able 
to inhibit the growth of various human tumour cell lines, 
including human histiocytic lymphoma (U-937), human breast 
carcinoma (mcF-7), human epithelial carcinoma (hela) and 
human myeloid lymphoma (ml-1a) (26). VEGi was also 
shown to inhibit tumour growth in vivo and to suppress the 
growth of colon carcinoma cells (murine colon cancer cells, 
mc-38) both in vitro and in vivo (7,27,28). parr et al reported 
that patients with breast tumours expressing reduced levels of 
VEGi had a higher local recurrence, shorter survival time and 
an overall poorer prognosis than those patients expressing high 
levels of VEGi. in addition, VEGi levels were lower in lobular 
tumours compared to tumours of ductal origin (9). However, 
it is unclear whether other mechanisms, such as activation of 
tumour-specific or non-specific B or T lymphocytes or induc-
tion of cytokines (29), are also involved in VEGI-mediated 
tumour suppression.
E-selectin (cd62E, Elam-1, lEcam-2) belongs to the 
selectin family, which features calcium-dependent type i 
transmembrane glycoproteins with extracellular lectin-like 
domains (30). It is specifically synthesized by endothelial 
cells and is not constitutively present. E-selectin is transcrip-
tionally regulated by several transcription factors, such as 
tumour necrosis factor α (tnFα), interleukin (il)-1, nF-κB 
and activator protein 1 (ap-1) (31,32). Once expressed on the 
cell surface, E-selectin is slowly internalized and directed to 
lysosomes for degradation (33). two major glycoprotein recep-
tors for E-selectin have been identified: the E-selectin ligand-1 
(ESl-1) and p-selectin glycoprotein ligand-1 (pSGl-1) (34,35). 
dr3 has been suggested as a new receptor for E-selectin 
which has been linked to cancer metastasis (13). the usual 
role of E-selectin is to mediate the adhesion of leukocytes to 
the endothelium allowing their extravasation into inflamed 
tissues. Inflammation and cancer metastasis are associated 
with extravasation of leukocytes or tumour cells from blood 
circulation into tissue. E-selectin, in part, is involved in these 
processes (36-42). 
liGht, a member of the tnF superfamily, is produced 
as a glycosylated 29-kDa type II transmembrane protein by 
activated t cells, monocytes, granulocytes and immature 
dendritic cells (43). its name is derived from homology to 
the lymphotoxins. liGht exhibits inducible expression and 
competes with herpes simplex virus glycoprotein d for herpes 
virus entry mediator, a receptor expressed by t lymphocytes. 
liGht binds to two functional cellular receptors, lympho-
toxin β receptor (ltβr) and herpes virus entry mediator 
(hVEm), as well as to a non-functional soluble dcr3 (44,45). 
the cytokine liGht activates various anti-tumour functions 
through the activation and augmentation of tumour immunity 
via ltβr and hVEm, and is expected to be a promising 
candidate for cancer therapy (46-49). DcR3 neutralizes the 
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biological effects of liGht and contributes to immune escape 
of tumours by binding to liGht.
FasL, Fas ligand (also known as CD95L), a type II membrane 
protein, belongs to the tnFr family (50,51). Fasl induces 
apoptosis upon receptor/ligand engagement. Fas/Fasl-mediated 
apoptosis is a normal and important homeostatic mechanism 
involved in the down-regulation of hyperimmune responses 
and the removal of activated lymphocytes (52). during carcino-
genesis, tumour cells develop many mechanisms to subvert the 
immune system and suppress the anti-tumour immune response, 
among which Fas and Fasl molecules play an important role 
in immune escape (53). it has been shown that cancer cells, 
such as breast, colon, gastric and esophageal carcinoma, may 
counterattack FAS-sensitive tumour-infiltrating lymphocytes 
(tils) via highly expressed FaSl. this mechanism may lead 
to a tumour cell immune privilege that sequentially contributes 
to cancer formation and progression (54-58). dcr3 is a decoy 
receptor for Fasl. Overexpression of dcr3 in tumours may 
be beneficial in terms of protecting against the cytotoxic and 
regulatory effects of Fasl (14). recent studies have shown a 
significant correlation between the expression levels of DcR3 
and FasL-inducing apoptosis (59).
4. Expression and cell/tissue distribution of DR3/DcR3
dr3 is preferentially expressed in peripheral blood leukocytes 
and in lymphocyte-rich tissues, including thymus and spleen, 
and to a lesser extent in the small intestine, colon, fetal lung, 
bone, ovary, brain, peripheral nervous system and fetal kidney 
(1,2,25,60-63). Some tumour cells also express dr3 (25,63,64). 
dr3 may be expressed in multiple forms by alternative 
splicing, for example osteoblasts express both transmembrane 
and soluble forms of dr3 (60). dcr3 is known as a soluble 
receptor. dcr3 expression has been noted in diverse tissues, 
including the colon, stomach, spleen, lymph node, spinal cord, 
pancreas and lung (14,15). compared to normal tissue, dcr3 
is overexpressed in malignant tumours from various organs, 
such as nasopharyngeal esophagus, laryngeal stomach, kidney, 
colon, liver, ovary and pancreas (15,65-72). 
Lupeol (Lup-20(29)-en-3H-ol), a novel dietary triterpene, 
was found to specifically cause a significant decrease in 
the expression of DR3 mRNA and protein and a significant 
elevation in expression of Fadd mrna in hepatocellular 
carcinoma Smmc7721 cells (73). hayashi et al found that 
tnFα increased dcr3 expression and inhibited Fas-induced 
apoptosis in rheumatoid arthritis from patients with fibro-
blast-like synoviocytes (74). another study demonstrated 
that insulin-like growth factor-1-induced activation of the 
phosphatidylinositol 3-kinase (pi3K)/akt/nF-κB signaling 
pathway is involved in the modulation of endogenous dcr3 
expression in aspc-1 cells, and reduced endogenous dcr3 
levels increase Fasl-induced apoptosis of human pancreatic 
cancer cells (69).
5. Functions of DR3/DcR3
the precise role and mechanism of dr3 in a physiopathologic 
context remains unclear. dr3 induces cellular apoptosis and 
proliferation via activation of the caspase apoptotic cascade 
or the transcription factor nuclear factor-κB (nF-κB), stress-
activated protein kinase (SapK), c-Jun n-terminal protein 
kinase (JnK) and p38 mitogen-activated protein kinase 
(mapK). dr3 contains a cytoplasmic death domain (dd), 
sharing certain similarity with TNFR1 and CD95. The 
signaling pathways induced by these receptors are similar and 
rely on the oligomerization of the receptors. upon binding 
with ligands, recruitment of death domain proteins, such as 
tradd, Fadd, tnF-receptor associated factor-2 (traF2), 
licE (Fadd-like interleukin 1β-converting enzyme) or 
rip1, through homophilic interaction of their death domains 
subsequently activate the caspase apoptotic cascade or the 
nF-κB pathway (2,11,22). constitutive activation of dr3 is 
prevented by interaction with the silencer of death domains 
(SOdd) (3). activation of dr3 by VEGi induces caspase 
activation and apoptosis in tF-1, human histiocytic lymphoma 
(U-937), human breast carcinoma (MCF-7), human epithelial 
carcinoma (hela) and human myeloid lymphoma (ml-1a), 
but not in t cells (8,26). VEGi binding to dr3 functions as a 
t cell co-stimulator, and VEGi production in monocytes leads 
to enhancement of t cell responses (8,75). however, Wen et al 
reported that the binding of tl1a to dr3 activated both the 
nF-κB and ErK pathway, while JnK and apoptosis-inhibiting 
protein c-iap2 prevented dr3-mediated apoptosis in tF-1 
cells. in this context, tl1a induces apoptosis in the presence 
of cycloheximide which subsequently blocks the synthesis of 
c-iap2 (12). a recent study suggested that dr3 is an E-selectin 
receptor on colon cancer cells. its activation by E-selectin trig-
gers the activation of p38, extracellular signal-regulated kinase 
(ErK), mapK pathways, and confers migration and survival 
advantages to cancer cells. dr3 is a death receptor, but its acti-
vation by E-selectin does not induce apoptosis in colon cancer 
cells, except when ErK is inhibited (13). 
dcr3 transducer antagonizes dr3-mediated apoptotic 
signals and other functions via competitive binding with 
VEGI, FasL and LIGHT (8,59,76-78). Moreover, Hsu et al 
demonstrated that dcr3 is capable of inducing actin reorga-
nization and enhancing the adhesion of monocytes and thp-1 
cells by activating multiple signaling molecules, such as 
protein kinase c (pKc), pi3K, focal adhesion kinase (FaK) 
and Src kinases. this suggests that soluble dcr3, similar to 
other immobilized members of the tnFr superfamily, is able 
to trigger ‘reverse signaling’ to modulate cell function (20).
6. Implications of DR3/DcR3 in carcinoma
the roles played by dr3 in cancer are controversial. tian et al 
reported that endothelial progenitor cells (Epcs) play a 
critical role in postnatal and tumour vasculogenesis. VEGi 
inhibits endothelial cell proliferation by inducing apoptosis, 
and this may be inhibited by neutralizing antibodies against 
DR3 or the recombinant extracellular domain of DR3 (79). 
however, reduced expression of dr3 has also been noted 
in hepatocellular carcinoma cells (Smmc7721) undergoing 
apoptosis induced by the chemopreventive agent lupeol (73). 
however, a recent study reported that dr3 is a new E-selectin 
counter-receptor that confers migration and survival 
advantages to colon carcinoma cells by triggering p38 and 
ErK mapK activation. they proposed that activation of 
dr3 by E-selectin acts as a switch that regulates metastasis 
by allowing colon carcinoma cells to escape apoptosis at the 
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benefit of migratory (p38) and survival (ERK) events (13). 
Fisetin, a natural flavonoid, inhibits DR3-mediated apoptosis 
and invasion in chemoresistant pancreatic cancer aspc-1 
cells induced by nF-κB (80). this suggests that dr3 may 
play crucial roles downstream of VEGi and other ligands in 
the regulation of survival and migration of cancer cells.
dcr3 inhibits cytotoxicity against tumour cells that is 
induced by Fas-Fasl and ltβr-liGht signaling, and inter-
feres with t cell co-stimulation mediated by hVEm-liGht 
association (14,74,81). liang et al found a positive correlation 
of dcr3 with the differentiation of colorectal carcinoma cells, 
lymph node metastasis and pathological stage. the over-
expression of dcr3 in colorectal cancer may contribute to the 
development of this cancer (67). dcr3 was also demonstrated 
as a predictive marker for 5-fluorouracil-based adjuvant 
chemotherapy in a study for colorectal cancer. in addition, 
expression of dcr3 in gastric carcinoma was found to be 
significantly higher compared to that in dysplasia, intestinal 
metaplasia and chronic superficial gastritis tissue. Moreover, 
dcr3 expression was found to correlate with local lymph 
node involvement and systemic metastasis (82,83). Gastric 
cancer patients with high dcr3 expression presented more 
advanced pn2-3 disease than those with low dcr3 expres-
sion. pre-operative assessment of dcr3 expression may be an 
additional approach to imaging modalities for evaluating n 
stages in gastric cancer to guide operative procedures (84,85). 
Overexpression of dcr3 was found to be associated with 
resistance to Fas ligand-mediated apoptosis (86,87). certain 
studies suggest that the expression of dcr3 may also be a 
useful prognostic factor in some types of cancers (70,88). in 
addition, dcr3 may have suppressive effects to down-regulate 
the host-immune system (89,90). 
7. Perspective
currently, little is known about dr3/dcr3 in cancer, particu-
larly their potential as anti-tumour targets. upon binding to 
dr3, VEGi was found to directly stimulate mouse dendritic 
cell maturation, which is an essential component of host 
immunity against cancer development (91). VEGI serves as 
a potential target in the development of angiogenesis-based 
cancer therapy. in contrast to the function of dr3, soluble 
dcr3 is generated to interfere with the autocrine function 
of VEGi (78). Enhanced expression of dcr3 has been indi-
cated in various solid tumours. this protects cancer cells 
and vascular endothelial cells from induced apoptosis and is 
positively correlated with tumour progression.
Further investigation of dr3/dcr3 and the associated 
signal pathways may expand the understanding of their role 
in cancer. this may provide a basis for tumour selective thera-
peutic targets, particularly for those associated with a defect 
in dr3/dcr3 signaling. interest in dr3/dcr3 is increasing. 
recently, morishige et al constructed dcr3-evading liGht 
mutants that may be powerful tools for cancer therapy (92). 
Wu et al generated monoclonal antibodies (mabs) against 
human dcr3 for the study of dcr3 expression, distribution in 
tissue and development of an ELISA kit (93). 
in summary, the aberrant expression and function of dr3/
dcr3 has been implicated in carcinoma. dr3/dcr3 is related to 
several ligands which have the ability to affect apoptosis, angio-
genesis and immune escape of tumours. Future studies should 
focus on elucidating their role in cancer under both physiological 
and pathological conditions. These findings may be useful for 
the diagnosis, differentiation, metastasis and determination of 
cancer stages. Furthermore, these may provide novel therapeutic 
approaches for targeting carcinomas in the future.
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